ATLANTA, GA -- October 16, 2006 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced the introduction of three new bio-imaging products to strengthen its commitment to enabling earlier detection of disease indicators and faster discovery of effective new drugs. The new tools, announced at the Neuroscience 2006 show in Atlanta, Georgia, fortify PerkinElmer’s increased focus on bio-imaging by offering high-performance, researchgrade systems and powerful software, providing scientists with greater insights into their research.

“From DNA to tissue analysis, PerkinElmer is dedicated to bio-imaging applications which enable biomedical researchers to advance the pace and precision of their research,” said Robert F. Friel, president of PerkinElmer Life and Analytical Sciences. “We are committed to meeting customer needs for innovative imaging tools and support that can meet the rigorous technical and workflow demands of a diverse range of medical, pharmaceutical, and research institutions.”

PerkinElmer’s new imaging products debuting at Neuroscience 2006 are:

• The Geliance™ family of gel imaging products for DNA, RNA and proteins – Gel imaging is a new offering in PerkinElmer’s bio-imaging family, and provides proteomic and genomic researchers with a system to help manage increasingly heavy workloads and meet ever-compressed deadlines. The Geliance family offers top-of-the- line optical performance, easy-to-use hardware, and software to customers looking for fluorescence and chemiluminescence imaging solutions. The Geliance 200 is designed for 1D fluorescence imaging and the Geliance 600 is intended for chemiluminescence imaging.
  
  
• The PhotoKinesis™ Accessory for the UltraVIEW^® Live Cell Imaging System –The accessory was designed to enable Fluorescence Recovery After Photobleaching (FRAP) and similar techniques to be performed on PerkinElmer’s UltraVIEW system. Researchers can now improve their ability to study fast-moving cells and rapid events in live cells, with point-and-click ease. The new “Track-It” technology offers real- time photoactivation and photoswitching for greater control over experiments and greater biologically relevant data from samples. Live cell imaging is understood to be the fastest-growing segment of the confocal microscopy market.
  
  
• The Spotlight™ 400 FT-IR Imaging System – The system is designed to enable labs to run more samples per day and provides greater understanding of materials with faster data collection, more sampling and longer unattended operating time. Spotlight imaging systems are now utilized in biomedical imaging research to detect disease indicators at earlier stages, given their excellent image quality and high- throughput performance for tissue analysis. When used with the new PerkinElmer ATR Imaging Accessory, scientists have a complete yet simple approach to analyze difficult samples that can allow for a reduced time-to-market of new products.

All three product introductions support PerkinElmer’s increased focus on the imaging market, with a significant investment in product development, and software and accessories, along with an enhanced focus on customer service and support.

For more information, visit www.perkinelmer.com .

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward- looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forwardlooking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.